J&J Full Steam Ahead On Separating Consumer Business While Inflation, Pandemic Slow Results
While target date for spinning out consumer business into publicly traded company remains some time in 2023, J&J includes additional details on separation timetable with its 2021 full-year and fourth-quarter results.
You may also be interested in...
Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.
Pharma R&D VP Mathai Mammen acknowledges “pros and cons to remaining” as one company but dismissed “any meaningful downside” for the pharma business, which along with the device business will continue operating as J&J.
Mayoly Spindler is stepping up its presence in the self-care market with the acquisition of Ipsen's Consumer Healthcare business, which has been under strategic review for the past year.